Genetics and pharmacogenomics of diffuse gliomas

Pharmacology and Therapeutics

Volumn 137, Issue 1, 2013, Pages 78-88

  Van Thuijl, H F ^a   Ylstra, B ^a   Wurdinger T ^a   Van Nieuwenhuizen, D ^a   Heimans, J J ^a   Wesseling, P ^a,b   Reijneveld, J C ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

1p 19q co deletion; Companion diagnostics; EGFRvIII; Glioma; IDH1; Pharmacogenomics

Indexed keywords

MICRORNA; MOLECULAR MARKER;

ARTICLE; ASTROCYTOMA; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER THERAPY; CHROMOSOME 10; CHROMOSOME 10P; CHROMOSOME 13Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 22Q; CHROMOSOME 7Q; CHROMOSOME 9P; CLINICAL TRIAL (TOPIC); COLORECTAL CARCINOMA; COPY NUMBER VARIATION; DRUG EFFICACY; EPIGENETICS; GENE DELETION; GLIOMA; HUMAN; LUNG CARCINOMA; MEDICAL DECISION MAKING; MELANOMA; OLIGODENDROGLIOMA; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; STOMACH CANCER;

EID: 84872300925     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.09.002     Document Type: Review

References (145)

1. K.D. Aldape, K. Ballman, A. Furth, J.C. Buckner, C. Giannini, and P.C. Burger Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance J Neuropathol Exp Neurol 63 2004 700 707
2. R.G. Amado, M. Wolf, M. Peeters, C.E. Van, S. Siena, and D.J. Freeman Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
3. P.P. Amaral, M.E. Dinger, T.R. Mercer, and J.S. Mattick The eukaryotic genome as an RNA machine Science 319 2008 1787 1789
4. V.J. Amatya, U. Naumann, M. Weller, and H. Ohgaki TP53 promoter methylation in human gliomas Acta Neuropathol 110 2005 178 184
5. F. Andre, N.E. Schartz, M. Movassagh, C. Flament, P. Pautier, and P. Morice Malignant effusions and immunogenic tumour-derived exosomes Lancet 360 2002 295 305
6. L.M. Backlund, B.R. Nilsson, H.M. Goike, E.E. Schmidt, L. Liu, and K. Ichimura Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN Clin Cancer Res 9 2003 4151 4158
7. L.M. Backlund, B.R. Nilsson, L. Liu, K. Ichimura, and V.P. Collins Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas Br J Cancer 93 2005 124 130
8. Y.J. Bang, C.E. Van, A. Feyereislova, H.C. Chung, L. Shen, and A. Sawaki Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
9. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A.A. Margolin, and S. Kim The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity Nature 483 2012 603 607
10. B. Basu, T.A. Yap, L.R. Molife, and J.S. de Bono Targeting the DNA damage response in oncology: past, present and future perspectives Curr Opin Oncol 24 2012 316 324
11. M. Benetkiewicz, A. Idbaih, P.Y. Cousin, B. Boisselier, Y. Marie, and E. Criniere NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas PLoS One 4 2009 e4107
12. R. Bernards It's diagnostics, stupid Cell 141 2010 13 17
13. C. Bettegowda, N. Agrawal, Y. Jiao, M. Sausen, L.D. Wood, and R.H. Hruban Mutations in CIC and FUBP1 contribute to human oligodendroglioma Science 333 2011 1453 1455
14. S.H. Bigner, B.K. Rasheed, R. Wiltshire, and R.E. McLendon Morphologic and molecular genetic aspects of oligodendroglial neoplasms Neuro Oncol 1 1999 52 60
15. M.D. Blough, M. Al-Najjar, C. Chesnelong, C.E. Binding, A.D. Rogers, and H.A. Luchman DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma Ann Neurol 71 2012 845 849
16. L.B. Bralten, S. Nouwens, C. Kockx, L. Erdem, C.C. Hoogenraad, and J.M. Kros Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas PLoS One 6 2011 e22000
17. B. Cadieux, T.T. Ching, S.R. VandenBerg, and J.F. Costello Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation Cancer Res 66 2006 8469 8476
18. G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, and D. Brachman Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J Clin Oncol 24 2006 2707 2714
19. J.G. Cairncross, K. Ueki, M.C. Zlatescu, D.K. Lisle, D.M. Finkelstein, and R.R. Hammond Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1998 1473 1479
20. J.A. Chan, A.M. Krichevsky, and K.S. Kosik MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells Cancer Res 65 2005 6029 6033
21. L.M. Chow, R. Endersby, X. Zhu, S. Rankin, C. Qu, and J. Zhang Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain Cancer Cell 19 2011 305 316
22. M.F. Corsten, R. Miranda, R. Kasmieh, A.M. Krichevsky, R. Weissleder, and K. Shah MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas Cancer Res 67 2007 8994 9000
23. R.P. Dematteo, K.V. Ballman, C.R. Antonescu, R.G. Maki, P.W. Pisters, and G.D. Demetri Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Lancet 373 2009 1097 1104
24. M. Dokmanovic, C. Clarke, and P.A. Marks Histone deacetylase inhibitors: overview and perspectives Mol Cancer Res 5 2007 981 989
25. L. Douw, M. Klein, S.S. Fagel, J. van den Heuvel, M.J. Taphoorn, and N.K. Aaronson Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up Lancet Neurol 8 2009 810 818
26. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, and S. Fanning Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
27. D. Duijvesz, T. Luider, C.H. Bangma, and G. Jenster Exosomes as biomarker treasure chests for prostate cancer Eur Urol 59 2011 823 831
28. S. Everhard, G. Kaloshi, E. Criniere, A. Benouaich-Amiel, J. Lejeune, and Y. Marie MGMT methylation: a marker of response to temozolomide in low-grade gliomas Ann Neurol 60 2006 740 743
29. E.B. Fauman, B.K. Rai, and E.S. Huang Structure-based druggability assessment-identifying suitable targets for small molecule therapeutics Curr Opin Chem Biol 15 2011 463 468
30. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
31. G. Gabriely, T. Wurdinger, S. Kesari, C.C. Esau, J. Burchard, and P.S. Linsley MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators Mol Cell Biol 28 2008 5369 5380
32. G. Gabriely, M. Yi, R.S. Narayan, J.M. Niers, T. Wurdinger, and J. Imitola Human glioma growth is controlled by microRNA-10b Cancer Res 71 2011 3563 3572
33. M.J. Garnett, E.J. Edelman, S.J. Heidorn, C.D. Greenman, A. Dastur, and K.W. Lau Systematic identification of genomic markers of drug sensitivity in cancer cells Nature 483 2012 570 575
34. R.J. Gillies, D. Verduzco, and R.A. Gatenby Evolutionary dynamics of carcinogenesis and why targeted therapy does not work Nat Rev Cancer 12 2012 487 493
35. J. Godlewski, M.O. Nowicki, A. Bronisz, S. Williams, A. Otsuki, and G. Nuovo Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal Cancer Res 68 2008 9125 9130
36. C.A. Griffin, P. Burger, L. Morsberger, R. Yonescu, S. Swierczynski, and J.D. Weingart Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss J Neuropathol Exp Neurol 65 2006 988 994
37. C. Hartmann, J. Meyer, J. Balss, D. Capper, W. Mueller, and A. Christians Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Acta Neuropathol 118 2009 469 474
38. L.H. Hartwell, P. Szankasi, C.J. Roberts, A.W. Murray, and S.H. Friend Integrating genetic approaches into the discovery of anticancer drugs Science 278 1997 1064 1068
39. M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, T.N. de, and M. Weller MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
40. A.B. Heimberger, D. Suki, D. Yang, W. Shi, and K. Aldape The natural history of EGFR and EGFRvIII in glioblastoma patients J Transl Med 3 2005 38
41. C. Horbinski, M.N. Nikiforova, J. Hobbs, S. Bortoluzzi, K. Cieply, and S. Dacic The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas J Neuropathol Exp Neurol 71 2012 73 82
42. C. Houillier, K. Mokhtari, C. Carpentier, E. Criniere, Y. Marie, and A. Rousseau Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas Neuro Oncol 12 2010 2 6
43. C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, R. Guillevin, and J. Laffaire IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 2010 1560 1566
44. http://www.genome.gov/sequencingcosts 2012 Ref Type: Online Source
45. K. Ichimura, M.B. Bolin, H.M. Goike, E.E. Schmidt, A. Moshref, and V.P. Collins Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities Cancer Res 60 2000 417 424
46. A. Idbaih, E. Criniere, K.L. Ligon, O. Delattre, and J.Y. Delattre Array-based genomics in glioma research Brain Pathol 20 2010 28 38
47. A. Idbaih, Y. Marie, G. Pierron, C. Brennetot, K. Hoang-Xuan, and M. Kujas Two types of chromosome 1p losses with opposite significance in gliomas Ann Neurol 58 2005 483 487
48. F.M. Iwamoto, L. Nicolardi, A. Demopoulos, V. Barbashina, P. Salazar, and M. Rosenblum Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas J Neurooncol 88 2008 293 298
49. S.P. Jackson, and J. Bartek The DNA-damage response in human biology and disease Nature 461 2009 1071 1078
50. J.W. Jeuken, A. Sijben, F.E. Bleeker, S.H. Boots-Sprenger, J. Rijntjes, and J.M. Gijtenbeek The nature and timing of specific copy number changes in the course of molecular progression in diffuse gliomas: further elucidation of their genetic «life story» Brain Pathol 21 2011 308 320
51. H. Joensuu Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec) Med Klin (Munich) 97 Suppl. 1 2002 28 30
52. O.P. Kallioniemi, A. Kallioniemi, J. Piper, J. Isola, F.M. Waldman, and J.W. Gray Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors Genes Chromosomes Cancer 10 1994 231 243
53. M. Kerick, M. Isau, B. Timmermann, H. Sultmann, R. Herwig, and S. Krobitsch Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity BMC Med Genomics 4 2011 68
54. S.N. Khleif, J.H. Doroshow, and W.N. Hait AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development Clin Cancer Res 16 2010 3299 3318
55. H. Kim, W. Huang, X. Jiang, B. Pennicooke, P.J. Park, and M.D. Johnson Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship Proc Natl Acad Sci U S A 107 2010 2183 2188
56. Y.H. Kim, J. Lachuer, M. Mittelbronn, W. Paulus, B. Brokinkel, and K. Keyvani Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations Brain Pathol 21 2011 645 651
57. Y.H. Kim, S. Nobusawa, M. Mittelbronn, W. Paulus, B. Brokinkel, and K. Keyvani Molecular classification of low-grade diffuse gliomas Am J Pathol 177 2010 2708 2714
58. M.C. Kouwenhoven, J.M. Kros, P.J. French, E.M. Biemond-ter Stege, W.J. Graveland, and M.J. Taphoorn 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment Eur J Cancer 42 2006 2499 2503
59. J. Laffaire, S. Everhard, A. Idbaih, E. Criniere, Y. Marie, and R.A. de Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis Neuro Oncol 13 2011 84 98
60. J. Lee, M.J. Son, K. Woolard, N.M. Donin, A. Li, and C.H. Cheng Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells Cancer Cell 13 2008 69 80
61. D.N. Louis The p53 gene and protein in human brain tumors J Neuropathol Exp Neurol 53 1994 11 21
62. D.N. Louis, H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, and A. Jouvet The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 2007 97 109
63. J. Lu, G. Getz, E.A. Miska, E. Alvarez-Saavedra, J. Lamb, and D. Peck MicroRNA expression profiles classify human cancers Nature 435 2005 834 838
64. B. Malzkorn, M. Wolter, F. Liesenberg, M. Grzendowski, K. Stuhler, and H.E. Meyer Identification and functional characterization of microRNAs involved in the malignant progression of gliomas Brain Pathol 20 2010 539 550
65. B. Malzkorn, M. Wolter, M.J. Riemenschneider, and G. Reifenberger Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets Brain Pathol 21 2011 619 632
66. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
67. L. Mariani, G. Deiana, E. Vassella, A.R. Fathi, C. Murtin, and M. Arnold Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy J Clin Oncol 24 2006 4758 4763
68. D.L. Masica, and R. Karchin Correlation of somatic mutation and expression identifies genes important in human glioblastoma progression and survival Cancer Res 71 2011 4550 4561
69. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 2005 9067 9072
70. P. Metellus, C. Carole, and A. Mausas de Paula Triple-negative low-grade gliomas: A highly agressive tumor with dismal prognosis Neuro Oncol 13 2011 iii41 iii68
71. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
72. N. Montano, T. Cenci, M. Martini, Q.G. D'Alessandris, F. Pelacchi, and L. Ricci-Vitiani Expression of EGFRvIII in glioblastoma: prognostic significance revisited Neoplasia 13 2011 1113 1121
73. R.P. Nagarajan, and J.F. Costello Epigenetic mechanisms in glioblastoma multiforme Semin Cancer Biol 19 2009 188 197
74. M. Nakamura, F. Yang, H. Fujisawa, Y. Yonekawa, P. Kleihues, and H. Ohgaki Loss of heterozygosity on chromosome 19 in secondary glioblastomas J Neuropathol Exp Neurol 59 2000 539 543
75. M. Nakamura, Y. Yonekawa, P. Kleihues, and H. Ohgaki Promoter hypermethylation of the RB1 gene in glioblastomas Lab Invest 81 2001 77 82
76. NCT00124657 Erlotinib and Radiation Therapy in Treating Young Patients with Newly Diagnosed Glioma www.clinicaltrials.gov 2011 Ref Type: Online Source
77. NCT00302159 Valproic Acid with Temozolomide and Radiation Thearpy to Treat Brain Tumors www.clinicaltrials.gov 2012 Ref Type: Online Source
78. NCT00626990 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial www.clinicaltrials.gov 2011 Ref Type: Online Source
79. NCT00823459 Phase II Trial of RAD001 in Patients with Recurrent Low Grade Glioma www.clinicaltrials.gov 2012 Ref Type: Online Source
80. NCT0087146 Phase III Intergroup Study of Radiotherapy Versus Temozolomide Alone Versus Radiotherapy With Concomitant and Adjuvant Temzolomide for Patients With 1p/19q Codeleted Anaplastic Glioma www.clinicaltrials.gov 2009 Ref Type: Online Source
81. NCT00895180 Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treatin Patients with Recurrent Glioblastoma Multiforme www.clinicaltrials. gov 2012 Ref Type: Online Source
82. NCT01051557 Temisrolimus and Perifosine in Treatin Patients with Recurrent of Progressive Malignant Glioma www.clinicaltrials.gov 2012 Ref Type: Online Source
83. NCT01067469 Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastome Multiforme www.clinicaltrials.gov 2012 Ref Type: Online Source
84. NCT01378481 Combination of Vorinostat and Radiation in the Treatment of Recurrent Glioma www.clinicaltrials.gov 2012 Ref Type: Online Source
85. NCT01390571 Olaparib and Temzolomide in Treating Patients with Relapsed Glioblastoma www.clinicaltrials.gov 2012 Ref Type: Online Source
86. NCT01402063 PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma without MGMT methylation www.clinicaltrials.gov 2012 Ref Type: Online Source
87. NCT01480479 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma www.clinicaltrials.gov 2012 Ref Type: Online Source
88. NCT01498328 A Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma (ReACT) www.clinicaltrials.gov 2012
89. NCT01562197 A Randomized Phase II Clinical Trial on Axitinib for the Treatment of Patients with Recurrent Glioblastoma (AxiG) www.clinicaltrials.gov 2012 Ref Type: Online Source
90. J.M. Nigro, S.J. Baker, A.C. Preisinger, J.M. Jessup, R. Hostetter, and K. Cleary Mutations in the p53 gene occur in diverse human tumour types Nature 342 1989 705 708
91. R.J. Nilsson, L. Balaj, E. Hulleman, R.S. van, D.M. Pegtel, and M. Walraven Blood platelets contain tumor-derived RNA biomarkers Blood 118 2011 3680 3683
92. J. Nilsson, J. Skog, A. Nordstrand, V. Baranov, L. Mincheva-Nilsson, and X.O. Breakefield Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer Br J Cancer 100 2009 1603 1607
93. H. Ohgaki, and P. Kleihues Genetic pathways to primary and secondary glioblastoma Am J Pathol 170 2007 1445 1453
94. R.A. Olson, P.K. Brastianos, and D.A. Palma Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis J Neurooncol 105 2011 325 335
95. A.E. Oostlander, G.A. Meijer, and B. Ylstra Microarray-based comparative genomic hybridization and its applications in human genetics Clin Genet 66 2004 488 495
96. K. Pantel, and C. Alix-Panabieres Circulating tumour cells in cancer patients: challenges and perspectives Trends Mol Med 16 2010 398 406
97. T. Papagiannakopoulos, A. Shapiro, and K.S. Kosik MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells Cancer Res 68 2008 8164 8172
98. D.W. Parsons, S. Jones, X. Zhang, J.C. Lin, R.J. Leary, and P. Angenendt An integrated genomic analysis of human glioblastoma multiforme Science 321 2008 1807 1812
99. D.M. Pegtel, K. Cosmopoulos, D.A. Thorley-Lawson, M.A. van Eijndhoven, E.S. Hopmans, and J.L. Lindenberg Functional delivery of viral miRNAs via exosomes Proc Natl Acad Sci U S A 107 2010 6328 6333
100. S. Pellegatta, L. Cuppini, and G. Finocchiaro Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas Expert Rev Anticancer Ther 11 2011 1759 1774
101. M. Pirmohamed Pharmacogenetics and pharmacogenomics Br J Clin Pharmacol 52 2001 345 347
102. G. Reifenberger, B. Hentschel, J. Felsberg, G. Schackert, M. Simon, and O. Schnell Predictive impact of MGMT promoter methylation in glioblastoma of the elderly Int J Cancer 131 2011 1342 1350
103. G. Reifenberger, and D.N. Louis Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology J Neuropathol Exp Neurol 62 2003 111 126
104. M.J. Riemenschneider, J.W. Jeuken, P. Wesseling, and G. Reifenberger Molecular diagnostics of gliomas: state of the art Acta Neuropathol 120 2010 567 584
105. P. Roerig, M. Nessling, B. Radlwimmer, S. Joos, G. Wrobel, and C. Schwaenen Molecular classification of human gliomas using matrix-based comparative genomic hybridization Int J Cancer 117 2005 95 103
106. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer Jr., and N.E. Davidson Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
107. F. Sahm, C. Koelsche, J. Meyer, S. Pusch, K. Lindenberg, and W. Mueller CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas Acta Neuropathol 123 2012 853 860
108. N. Schmidt, S. Windmann, G. Reifenberger, and M.J. Riemenschneider DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas Brain Pathol 22 2012 17 25
109. J. Schwartzentruber, A. Korshunov, X.Y. Liu, D.T. Jones, E. Pfaff, and K. Jacob Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma Nature 482 2012 226 231
110. H. Schwarzenbach, D.S. Hoon, and K. Pantel Cell-free nucleic acids as biomarkers in cancer patients Nat Rev Cancer 11 2011 426 437
111. L. Shi, J. Chen, J. Yang, T. Pan, S. Zhang, and Z. Wang MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity Brain Res 1352 2010 255 264
112. L. Shi, S. Zhang, K. Feng, F. Wu, Y. Wan, and Z. Wang MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis Int J Oncol 40 2012 119 129
113. J. Skog, T. Wurdinger, R.S. van, D.H. Meijer, L. Gainche, and M. Sena-Esteves Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers Nat Cell Biol 10 2008 1470 1476
114. O. Slaby, R. Lakomy, P. Fadrus, R. Hrstka, L. Kren, and E. Lzicarova MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients Neoplasma 57 2010 264 269
115. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
116. S.J. Smeets, U. Harjes, W.N. van Wieringen, D. Sie, R.H. Brakenhoff, and G.A. Meijer To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic! Clin Cancer Res 17 2011 4959 4964
117. M. Smits, S.E. Mir, R.J. Nilsson, P.M. van der Stoop, J.M. Niers, and V.E. Marquez Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2 PLoS One 6 2011 e16282
118. M. Smits, J. Nilsson, S.E. Mir, P.M. van der Stoop, E. Hulleman, and J.M. Niers miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis Oncotarget 1 2010 710 720
119. A.M. Snijders, N. Nowak, R. Segraves, S. Blackwood, N. Brown, and J. Conroy Assembly of microarrays for genome-wide measurement of DNA copy number Nat Genet 29 2001 263 264
120. M. Snuderl, L. Fazlollahi, L.P. Le, M. Nitta, B.H. Zhelyazkova, and C.J. Davidson Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma Cancer Cell 20 2011 810 817
121. TCGA Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
122. C. Thery, M. Ostrowski, and E. Segura Membrane vesicles as conveyors of immune responses Nat Rev Immunol 9 2009 581 593
123. J.H. Tjio, and A. Levan The chromosome number of man Hereditas 42 1956 1 6
124. B. Tran, J.E. Dancey, S. Kamel-Reid, J.D. McPherson, P.L. Bedard, and A.M. Brown Cancer genomics: technology, discovery, and translation J Clin Oncol 30 2012 647 660
125. D. Trost, M. Ehrler, R. Fimmers, J. Felsberg, M.C. Sabel, and L. Kirsch Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors Int J Cancer 120 2007 2368 2376
126. S. Turcan, D. Rohle, A. Goenka, L.A. Walsh, F. Fang, and E. Yilmaz IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 2012 479 483
127. N.C. Turner, and J.S. Reis-Filho Genetic heterogeneity and cancer drug resistance Lancet Oncol 13 2012 e178 e185
128. K. Uhlmann, K. Rohde, C. Zeller, J. Szymas, S. Vogel, and K. Marczinek Distinct methylation profiles of glioma subtypes Int J Cancer 106 2003 52 59
129. K. Ujifuku, N. Mitsutake, S. Takakura, M. Matsuse, V. Saenko, and K. Suzuki miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells Cancer Lett 296 2010 241 248
130. M. Van den Bent, K. Hoang-Xuan, and A.A. Brandes Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) J Clin Oncol 30 2012
131. A.C. Van Prooijen-Knegt, J.F. Van Hoek, J.G. Bauman, D.P. Van, I.G. Wool, and M. Van der Ploeg In situ hybridization of DNA sequences in human metaphase chromosomes visualized by an indirect fluorescent immunocytochemical procedure Exp Cell Res 141 1982 397 407
132. R.G. Verhaak, K.A. Hoadley, E. Purdom, V. Wang, Y. Qi, and M.D. Wilkerson Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 17 2010 98 110
133. T. Watanabe, Y. Katayama, A. Yoshino, C. Komine, and T. Yokoyama Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course Clin Cancer Res 9 2003 4884 4890
134. T. Watanabe, S. Nobusawa, P. Kleihues, and H. Ohgaki IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas Am J Pathol 174 2009 1149 1153
135. I.B. Weinstein, and A.K. Joe Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy Nat Clin Pract Oncol 3 2006 448 457
136. M. Weller, T. Gorlia, J.G. Cairncross, M.J. van den Bent, W. Mason, and K. Belanger Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma Neurology 77 2011 1156 1164
137. P.Y. Wen, E.Q. Lee, D.A. Reardon, K.L. Ligon, and W.K. Alfred Yung Current clinical development of PI3K pathway inhibitors in glioblastoma Neuro Oncol 14 2012 819 829
138. W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai, and M. Simon Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 7 2012 707 715
139. T. Wurdinger, and F.F. Costa Molecular therapy in the microRNA era Pharmacogenomics J 7 2007 297 304
140. T. Wurdinger, B.A. Tannous, O. Saydam, J. Skog, S. Grau, and J. Soutschek miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells Cancer Cell 14 2008 382 393
141. S. Yip, Y.S. Butterfield, O. Morozova, S. Chittaranjan, M.D. Blough, and J. An Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers J Pathol 226 2012 7 16
142. B. Ylstra, I. van d, B. Carvalho, R.H. Brakenhoff, and G.A. Meijer BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH) Nucleic Acids Res 34 2006 445 450
143. S. Zhang, Y. Wan, T. Pan, X. Gu, C. Qian, and G. Sun MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide J Mol Neurosci 47 2012 346 356
144. X. Zhang, H. Yang, B. Gong, C. Jiang, and L. Yang Combined gene expression and protein interaction analysis of dynamic modularity in glioma prognosis J Neurooncol 107 2012 281 288
145. W. Zhang, J. Zhang, K. Hoadley, D. Kushwaha, V. Ramakrishnan, and S. Li miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression Neuro Oncol 14 2012 712 719